Streamlined quality assessments of new and improved vaccines and therapeutics for emerging variants of the SARS-CoV-2 virus outlined in 22 February US Food and Drug Administration guidance should expedite authorization once there is international agreement on when to use them.
Of particular concern is the B.1.351 variant seen first in South Africa because studies suggest it reduces efficacy of vaccines...





